Cirugia y cirujanos · 2025
Evaluation of mediastinal lymphadenopathy from long-term radiological findings in COVID-19.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ayhan-Albayrak Gulhan, Bardakci Mustafa I
Аннотация
OBJECTIVE: Mediastinal lymphadenopathy (MLAP) has been reported in post-COVID-19 patients. In this study, the relationship between post-COVID-19 infection and MLAP was investigated in patients who had been diagnosed with MLAP and decided to undergo surgery.
METHODS: The study included the records of 140 patients who had been diagnosed with MLAP and were decided for surgical treatment. Demographic findings, reverse transcription-polymerase chain reaction (PCR) test results, chest X-ray, thorax computed tomography (CT) findings, positron emission tomography (PET)-CT findings, and histopathological results were recorded.
RESULTS: SUVmax value above 2.5 was 15 times more common in patients with positive PCR test results than in patients with negative results. Abnormal chest X-ray results were associated with a 9.3-fold increase in the number of patients, and the number of patients with abnormal pathology results was 33.9 times higher than those with normal results.
CONCLUSIONS: Post-COVID-19 and MLAP (SUVmax 3-5) were shown to be associated independently of age, gender, comorbidities, and disease outcomes. MLAP lesions in patients with COVID-19 demonstrated SUVmax values that were 10-fold higher compared to patients without COVID-19. Determining reliable SUVmax values in patients with severe COVID-19 may help guide clinical decisions, tailor therapeutic approaches, and avoid unnecessary surgical indications.
METHODS: The study included the records of 140 patients who had been diagnosed with MLAP and were decided for surgical treatment. Demographic findings, reverse transcription-polymerase chain reaction (PCR) test results, chest X-ray, thorax computed tomography (CT) findings, positron emission tomography (PET)-CT findings, and histopathological results were recorded.
RESULTS: SUVmax value above 2.5 was 15 times more common in patients with positive PCR test results than in patients with negative results. Abnormal chest X-ray results were associated with a 9.3-fold increase in the number of patients, and the number of patients with abnormal pathology results was 33.9 times higher than those with normal results.
CONCLUSIONS: Post-COVID-19 and MLAP (SUVmax 3-5) were shown to be associated independently of age, gender, comorbidities, and disease outcomes. MLAP lesions in patients with COVID-19 demonstrated SUVmax values that were 10-fold higher compared to patients without COVID-19. Determining reliable SUVmax values in patients with severe COVID-19 may help guide clinical decisions, tailor therapeutic approaches, and avoid unnecessary surgical indications.